期刊文献+

柱前衍生高效液相色谱法检测人血浆及尿液中左卡尼汀含量 被引量:3

Study on the method for determination of human plasma and urine L-carnitine by precolumn derivatization HPLC
下载PDF
导出
摘要 目的:通过柱前衍生化后高效液相色谱法检测人血浆和尿液左卡尼汀含量。方法:采用Hypersil SiO2色谱柱,Waters2695高效液相色谱系统,用衍生化的方法处理血样和尿样,绘制标准曲线,测定精密度、回收率和稳定性,检测正常人血浆及尿液的左卡尼汀含量。结果:本方法血浆样品的回归方程为Y=0.02861X+0.01190,r=0.9980,线性范围为5~320μmol·L^-1。尿液样品的线性回归方程为Y。0.0786X+0.02620,r=0.9969,线性范围为5~320μmol·L^-1。RSD小于4%,回收率大于90%,稳定性良好。结论:本方法灵敏、准确、快速、简便,适用于临床同时检测血浆和尿液中左卡尼汀的浓度。 OBJECTIVE To establish an improved method in determination of plasma and urine L-carnitine by precolumn derivatization HPLC. METHODS The plasma and urine samples were derivatized, standard curves were drawn and the plasma and urine levels of L-carnitine were determined by HPLC with Hypersil SiO2 chromatographic column. RESULTS The regression equation of plasma was Y = 0. 028 61X + 0.011 90, r = 0. 998 0, the regression equation of urine was Y = 0. (178 6X + 0. 026 20, r= 0. 996 9. The precision RSD was less than 4%, the sample recovery was above 90%. The stability was good. CONCLUSION The improved method of determination plasma and urine L-carnitine by HPLC precolumn derivatization is sen sitive, fast, reliable and convenient and can be used for clinic determination.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2008年第15期1265-1268,共4页 Chinese Journal of Hospital Pharmacy
关键词 高效液相色谱法 衍生化 左卡尼汀 血浆 尿液 HPLC derivatization L-carnitine plasma urine
  • 相关文献

参考文献11

二级参考文献26

  • 1[1]Borum PR. Plasma carnitine compartment and red blood cell carnitine compartment of healthy adults. Am J Clin Nutr, 1987,46:437-441 被引量:1
  • 2[2]Suzuki M, Tokuyama K, Kinoshita M.Urinary profile of L-carnitine and its derivates in starved normal persons and ACTH injected patients with myopathy. J Nutr Sci Vitaminol,1983, 29:303-312 被引量:1
  • 3[3]Borum PR. Changing perspective of carnitine function and the need for exogenous carnitine of patients treated with hemodialysis. Am J Clin Nutr,1996,976-977 被引量:1
  • 4[4]Sahajwalla CG, Helton ED, Parich,ED et al. Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20 mg/kg intravenous dose. J Pharma Sci, 1995,84:634-639 被引量:1
  • 5[5]Gloggler A, Bulla M, Furst P. Kinetics of intravenously administered carnitine in hemodialysised children . J Pharmacentical &Biomedical Analysis, 1990,8(5):411-414 被引量:1
  • 6[6]Evans AM, Faull R, Fornasini G,et al. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther,2000,68:238-249 被引量:1
  • 7Golper TA, Wolfson M, Ahmad S, et al. Multicentre trial of L - carni-tine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney 1nt,1990,38:904. 被引量:1
  • 8Rossle C,Kohse KP,Franz HE,et al. An improved method for the determination of free and esterfied carnitine. Clin Chem Acta, 1985,149 :263. 被引量:1
  • 9Fuller RK, Hoppel CL. Elevated plasma carnitine in hepatic cirrhosis.Hepatology, 1983,3 (4) :554. 被引量:1
  • 10Minkler PE ,Ingalls ST, Hoppel. High- performance liquid chromatographic separation of acylcarnitines following derivatization with 4'-bromophenacyl trifluoromethylsulfonate. Anal Biochem, 1990,185.29. 被引量:1

共引文献61

同被引文献38

  • 1孙永旭,陆丛笑,唐启令,曹玉,薛玉增,万秀霞,王春波.高效液相色谱法同时测定人血浆中左卡尼汀、乙酰左卡尼汀和丙酰左卡尼汀的浓度[J].中国药学杂志,2007,42(18):1425-1428. 被引量:7
  • 2Moselhy SS,Demerdash SH.Serum free L-camitine in as- sociation with myoglobin as a diagnostic marker of acute myocardial infarction[J].Clin Biochem, 2009,42 (1-2) : 78- 82. 被引量:1
  • 3屈明朗.番茄红素拮抗氧化应激诱导的神经元损伤及分子机制研究[D].重庆:第三军医大学,2012. 被引量:1
  • 4Neri S, Pistone G, Saraceno B ,et al.L-camitine decreas- es severity and type of fatigue induced by interferon-al- pha in the treatment of patients with hepatitis C[J].Neu- ropsychobiology, 2003,47 (2) : 94-97. 被引量:1
  • 5Kajimoto Y,Kaneto H.Role of oxidative stress in pancre atic beta-cell dysfunction[J].Ann N Y Acad Sci, 2004, 1011 : 168-176. 被引量:1
  • 6Fuller RK, Hoppel CL.Elevated plasma camitine in hep- atic cirrhosis[J].Hepathology, 1983,3(4) :554-558. 被引量:1
  • 7国家药典委员会.国家食品药品监督管理局·国家药品标准·新药转正标准·第64册[Z].2008:128-129. 被引量:1
  • 8国家药典委员会.国家食品药品监督管理局·国家药品标准·新药转正标准·第61册[Z].2008:221. 被引量:1
  • 9European Directorate for the Quality of Medicines & HealthCare.European Pharmacopoeia [Z].6th.2008 : 2257- 2258. 被引量:1
  • 10The United States Pharmacopoeia,USP32-NF27[Z].2009: 2766-2768. 被引量:1

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部